| P50 | author | Jose Garnacho-Montero | Q56867748 |
| P2093 | author name string | C León Gil | |
| P2860 | cites work | Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group | Q73321118 |
| | Candiduria in critically ill patients admitted to intensive care medical units | Q73413836 |
| | Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group | Q73521790 |
| | Guidelines for treatment of candidiasis | Q75213797 |
| | Economic impact of Candida colonization and Candida infection in the critically ill patient | Q79783221 |
| | Invasive aspergillosis in critically ill patients without malignancy | Q80269940 |
| | Candida colonization and subsequent infections in critically ill surgical patients | Q24535524 |
| | Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome | Q24811601 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis | Q28377349 |
| | The epidemiology of sepsis in the United States from 1979 through 2000 | Q29547760 |
| | Mortality and costs of acute renal failure associated with amphotericin B therapy | Q32068576 |
| | Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 |
| | Epidemiology of Candida species infections in critically ill non-immunosuppressed patients | Q34273626 |
| | Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 |
| | Treatment of severe Candida infections in high-risk patients in Germany: consensus formed by a panel of interdisciplinary investigators | Q34694325 |
| | Combinations of antifungal agents in therapy--what value are they? | Q35890888 |
| | Is it time to abandon the use of amphotericin B bladder irrigation? | Q36103620 |
| | Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia | Q40524745 |
| | Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients | Q40624651 |
| | Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature | Q41218000 |
| | Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care. | Q41753239 |
| | NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis | Q42599568 |
| | The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy | Q43797281 |
| | Immunoparalysis as a cause for invasive aspergillosis? | Q43798573 |
| | Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 |
| | Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study | Q44352517 |
| | Disseminated aspergillosis in intensive care unit patients: an autopsy study | Q44392075 |
| | A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. | Q44440960 |
| | Amphotericin B: time for a new "gold standard". | Q44527998 |
| | Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. | Q44731146 |
| | Combination antifungal therapy for invasive aspergillosis | Q45096994 |
| | Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy | Q45172488 |
| | Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients | Q45187465 |
| | In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. | Q45200724 |
| | Candidemia in critically ill patients: difference of outcome between medical and surgical patients | Q47619707 |
| | Practices in non-neutropenic ICU patients with Candida-positive airway specimens | Q47980212 |
| | Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. | Q53950594 |
| | Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. | Q54063081 |
| | The Role of Candida sp Isolated From Bronchoscopic Samples in Nonneutropenic Patients | Q57238103 |
| | Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: Report of Eight Cases and Review | Q57238104 |
| | Nosocomial infections in combined medical-surgical intensive care units in the United States | Q64130367 |
| | Risk factors for hospital-acquired candidemia. A matched case-control study | Q69771679 |
| | A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 |
| | Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU | Q73083415 |
| | Failure of a lipid amphotericin B preparation to eradicate candiduria: preliminary findings based on three cases | Q73104967 |
| P433 | issue | 4 | |
| P304 | page(s) | 283-289 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria | Q26842251 |
| P1476 | title | [Summary of therapy recommendations for fungal infection in the non-neutropenic critical-care patient: a multidisciplinary view] | |
| P478 | volume | 29 | |